David Anderson - Jul 14, 2023 Form 4 Insider Report for ALPHA HEALTHCARE ACQUISITION CORP III (CTCX)

Role
Director
Signature
/s/ Randolph W. Hubbell, Attorney-in-Fact
Stock symbol
CTCX
Transactions as of
Jul 14, 2023
Transactions value $
$0
Form type
4
Date filed
7/18/2023, 08:32 PM
Previous filing
Apr 4, 2022
Next filing
Dec 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTCX Stock Option (right to buy) Award +16.3 K 16.3 K Jul 14, 2023 Common Stock 16.3 K $1.79 Direct F1, F4
transaction CTCX Stock Option (right to buy) Award +19.9 K 19.9 K Jul 14, 2023 Common Stock 19.9 K $1.79 Direct F1, F4
transaction CTCX Stock Option (right to buy) Award +8.51 K 8.51 K Jul 14, 2023 Common Stock 8.51 K $2.27 Direct F2, F4
transaction CTCX Stock Option (right to buy) Award +32.2 K 32.2 K Jul 14, 2023 Common Stock 32.2 K $2.11 Direct F3, F4

Explanation of Responses:

Id Content
F1 Options are fully vested and exercisable.
F2 Options to purchase 8,509 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: (i) 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% will vest on July 19, 2023.
F3 Options to purchase 32,173 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F4 On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.